Palbociclib In Progressive Brain Metastases

NCT02896335

Last updated date
Study Location
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
Contact
617-724-8770

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

617-724-8770

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic Malignant Neoplasm to Brain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Participants must have histologically or cytologically confirmed disease from any solid tumor

- Participants must have measurable disease in the CNS, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm .

- Participants must have progressive CNS lesions, as defined by one of the following:

- Patients may have multiple progressive CNS lesions, some of which have been treated by SRS or surgery. Patients are eligible if they have one or more un-treated (by surgery or SRS) progressive lesions that is measurable.

- Patients have measurable residual or progressive lesions after surgery.

- Patients who have had prior WBRT and/or SRS are eligible but there needs to be unequivocal evidence of progression of at least one lesion treated by radiation (e.g. tissue diagnosis). Biopsy can be considered for definitive diagnosis.

- Patients who have previously been treated with systemic therapy for CNS metastases are eligible.

- Age ≥ 18 years. The toxicity of palbociclib in children is unknown.

- ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)

- Participants must have normal organ and marrow function as defined below:

- leukocytes ≥3,000/mcL

- absolute neutrophil count ≥1,500/mcL

- platelets ≥100,000/mcL

- hemoglobin >9g/dL

- total bilirubin ≤ 1.5 x institutional upper limit of normal

--- OR

- > 1.5 x institutional upper limit of normal allowed if direct bilirubin is within normal range.

- AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal

- creatinine within normal institutional limits

--- OR

- creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.

- baseline QTc <480ms

- The effects of palbociclib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of palbociclib administration.

- Ability to understand and the willingness to sign a written informed consent document.

- Tissue from a prior craniotomy or biopsy for genetic sequencing (at least one FFPE block or 15 unstained slides). Patients previously assessed for genetic sequencing who meet requirements of section 9.2.1 do not need to have additional tissue available for prospective genetic sequencing.

- Presence of alteration in CDK pathway (amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A)

- Patients with progressive extracranial disease will not be excluded.

- Stable corticosteroids for at least 7 days

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Prior treatment with CDK4/6 inhibitor


- Participants who have had chemotherapy, immunotherapy or radiotherapy within 2 weeks
(6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who
have not recovered from adverse events due to agents administered more than 2 weeks
earlier.


- Participants who are receiving any other investigational agents


- Participants who are receiving other concurrent chemotherapies or immunotherapies for
their cancer (except for patients who will receive letrozole, anastrozole, exemestane,
tamoxifen, fulvestrant, trastuzumab, bisphosphonates, or ovarian suppression therapy)


- Leptomeningeal involvement of cancer


- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to palbociclib (including abemaciclib)


- Participants receiving any medications or substances that are moderate or strong
inhibitors or inducers of CYP3A isoenzymes are ineligible. Lists including medications
and substances known or with the potential to interact with the CYP3A isoenzymes are
provided in Appendix C, and can also be found within section 5.4. Because the lists of
these agents are constantly changing, it is important to regularly consult a
frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx;
medical reference texts such as the Physicians' Desk Reference may also provide this
information. As part of the enrollment/informed consent procedures, the patient will
be counseled on the risk of interactions with other agents, and what to do if new
medications need to be prescribed or if the patient is considering a new
over-the-counter medicine or herbal product.


- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.


- Pregnant women are excluded from this study because the effect of palbociclib on a
developing fetus is unknown. Because there is an unknown but potential risk for
adverse events in nursing infants secondary to treatment of the mother with
palbociclib, breastfeeding should be discontinued if the mother is treated with
palbociclib.


- HIV-positive participants on combination antiretroviral therapy are ineligible because
of the potential for pharmacokinetic interactions with palbociclib. In addition, these
participants are at increased risk of lethal infections when treated with
marrow-suppressive therapy. Appropriate studies will be undertaken in participants
receiving combination antiretroviral therapy when indicated.


- Current use of drugs that are known to prolong the QT interval (See Appendix C)


- Unable to undergo MRI scans.


- QTc>480 msec (based on the mean value of the triplicate ECGs), family or personal
history of long or short QTc prolongation, or Torsade de Pointes (TdP).


- Uncontrolled electrolyte disorders that can compound the effects of QTc-prolonging
drug (eg. hypocalcemia, hypokalemia, hypomagnesemia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Metastatic Malignant Neoplasm to BrainPalbociclib In Progressive Brain Metastases
NCT02896335
  1. Boston, Massachusetts
  2. Boston, Massachusetts
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Palbociclib In Progressive Brain Metastases
Official Title  ICMJE A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway
Brief Summary

This research study is studying palbociclib as a possible treatment for recurrent brain metastases.

- Pfizer, a pharmaceutical company, is supporting this research study by providing the study drug as well as funding for research activities

Detailed Description
  • This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.
  • This is a study designed to evaluate the efficacy and safety of palbociclib in recurrent brain metastases. Palbociclib is being studied for use in the treatment of a broad range of cancers. This type of drug inhibits cell growth in the cells called cyclin-dependent kinases which promote tumor cell proliferation.
  • The FDA (the U.S. Food and Drug Administration) has not approved palbociclib for participants specific disease but it has been approved for other uses
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Malignant Neoplasm to Brain
Intervention  ICMJE Drug: Palbociclib
Other Name: Ibrance
Study Arms  ICMJE Experimental: Palbociclib

Description Patients who fulfill eligibility criteria will be entered into the trial to receive Palbociclib

After the screening procedures confirm participation in the research study:

  • Palbociclib- Fixed Dose, daily for 21 days per cycle.
  • The participant will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle.
Intervention: Drug: Palbociclib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 9, 2016)
30
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 2024
Estimated Primary Completion Date September 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participants must have histologically or cytologically confirmed disease from any solid tumor
  • Participants must have measurable disease in the CNS, defined as at least one lesion that can be accurately measured in at least one dimension as ?10 mm .
  • Participants must have progressive CNS lesions, as defined by one of the following:

    • Patients may have multiple progressive CNS lesions, some of which have been treated by SRS or surgery. Patients are eligible if they have one or more un-treated (by surgery or SRS) progressive lesions that is measurable.
    • Patients have measurable residual or progressive lesions after surgery.
    • Patients who have had prior WBRT and/or SRS are eligible but there needs to be unequivocal evidence of progression of at least one lesion treated by radiation (e.g. tissue diagnosis). Biopsy can be considered for definitive diagnosis.
    • Patients who have previously been treated with systemic therapy for CNS metastases are eligible.
  • Age ? 18 years. The toxicity of palbociclib in children is unknown.
  • ECOG performance status ?2 (Karnofsky ?60%, see Appendix A)
  • Participants must have normal organ and marrow function as defined below:

    • leukocytes ?3,000/mcL
    • absolute neutrophil count ?1,500/mcL
    • platelets ?100,000/mcL
    • hemoglobin >9g/dL
    • total bilirubin ? 1.5 x institutional upper limit of normal

      --- OR

    • > 1.5 x institutional upper limit of normal allowed if direct bilirubin is within normal range.
    • AST(SGOT)/ALT(SGPT) ?2.5 × institutional upper limit of normal
    • creatinine within normal institutional limits

      --- OR

    • creatinine clearance ?60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.
    • baseline QTc <480ms
  • The effects of palbociclib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of palbociclib administration.
  • Ability to understand and the willingness to sign a written informed consent document.
  • Tissue from a prior craniotomy or biopsy for genetic sequencing (at least one FFPE block or 15 unstained slides). Patients previously assessed for genetic sequencing who meet requirements of section 9.2.1 do not need to have additional tissue available for prospective genetic sequencing.
  • Presence of alteration in CDK pathway (amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A)
  • Patients with progressive extracranial disease will not be excluded.
  • Stable corticosteroids for at least 7 days

Exclusion Criteria:

  • Prior treatment with CDK4/6 inhibitor
  • Participants who have had chemotherapy, immunotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier.
  • Participants who are receiving any other investigational agents
  • Participants who are receiving other concurrent chemotherapies or immunotherapies for their cancer (except for patients who will receive letrozole, anastrozole, exemestane, tamoxifen, fulvestrant, trastuzumab, bisphosphonates, or ovarian suppression therapy)
  • Leptomeningeal involvement of cancer
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib (including abemaciclib)
  • Participants receiving any medications or substances that are moderate or strong inhibitors or inducers of CYP3A isoenzymes are ineligible. Lists including medications and substances known or with the potential to interact with the CYP3A isoenzymes are provided in Appendix C, and can also be found within section 5.4. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated list such as http://medicine.iupui.edu/clinpharm/ddis/table.aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because the effect of palbociclib on a developing fetus is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with palbociclib, breastfeeding should be discontinued if the mother is treated with palbociclib.
  • HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with palbociclib. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
  • Current use of drugs that are known to prolong the QT interval (See Appendix C)
  • Unable to undergo MRI scans.
  • QTc>480 msec (based on the mean value of the triplicate ECGs), family or personal history of long or short QTc prolongation, or Torsade de Pointes (TdP).
  • Uncontrolled electrolyte disorders that can compound the effects of QTc-prolonging drug (eg. hypocalcemia, hypokalemia, hypomagnesemia
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Priscilla Brastianos, MD617-724-8770[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02896335
Other Study ID Numbers  ICMJE 16-254
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party Priscilla Brastianos, Massachusetts General Hospital
Study Sponsor  ICMJE Massachusetts General Hospital
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Priscilla Brastianos, MDMassachusetts General Hospital
PRS Account Massachusetts General Hospital
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP